Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Corporate Update (December 2018)
13 slides from Indivior Pharmaceuticals's corporate update, Dec 18, 2018
Slide 1: Indivior Trading Update
Indivior Trading Update December 18th 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain statements that are forward-looking and which should be considered, amongst other statutory provisions, in light of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. By their nature, forwar
Slide 3: Legal Update
Legal Update SZ INDIVIOR AS
Slide 4: ANDA Litigation Update
ANDA Litigation Update Dr. Reddy’s Laboratories (DRL) Preliminary Injunction (PI) • On November 20, the Court of Appeals for the Federal Circuit (CAFC) vacated the PI against DRL. The PI will remain in place (and DRL is unable to launch), until the CAFC issues the mandate, which is a formal filing i
Slide 5: Key ANDA Litigation Milestones
Key ANDA Litigation Milestones Event Estimated Date Federal Circuit ruling on whether to grant Indivior’s petition for rehearing Q1 2019 Q2 2019 if rehearing; Federal Circuit ruling if rehearing/rehearing en banc is granted Q3 2019 if en banc Federal Circuit Court ruling in appeal of ‘514 patent non
Slide 6: FY 2018 Financial Guidance
FY 2018 Financial Guidance SZ INDIVIOR AS
Slide 7: Expect to meet guidance for FY 2018
Expect to meet guidance for FY 2018 FY 2018 Guidance ($ in mil.) Net Revenue $990m - $1,020m Net Income $230m - $255m Top-line: Expenses: • US market conditions • Pre-tax savings of $55 million from cost actions the Group has taken to streamline ✓ ‘At-risk’ generic film entry in FY 2019 at earliest
Slide 8: SUBLOCADE Update
SUBLOCADE™ Update Sublocade (buprenorphine extended-release) injection for subcutaneous use & 100mg-300mg Nz AS INDIVIOR
Slide 9: First SUBLOCADE Prescription Journey Timeline – Journey Process Reduction
First SUBLOCADE™ Prescription Journey Timeline – Journey Process Reduction Drivers of Journey Time Reduction 43 to 62 Calendar Days to Dispense 16 to 23 70.0 • Education of HCP office staff by Field Reimbursement (FRS) team 60.0 3-5 • Accuracy of patient application 50.0 10-15 • Payor coverage (quan
Slide 10: 14,630+ Unique prescriptions initiated
The Number of Unique Patients Injected with SUBLOCADE™ Increased Month Over Month Closed Case Performance (1)(2) Closed case run-rate: 94% 94% 85% 80% 65% Cumulative Launch to 11/30/18 (1) 100% 90% 80% 83% ~65% initial Payor coverage 70% 70% 66% 63% 64% 63% approval rate for SUBOXONE® Film(3) 60% ~5
Slide 11: SUBLOCADE KPIs – HCP Data & Patient Treatment Adherence
SUBLOCADE™ KPIs – HCP Data & Patient Treatment Adherence Treatment Adherence (All patients with initial injection during March to Sept) 2,270 HCPs initiated prescription journeys 100% 80% 73% 1,195 HCPs administered SUBLOCADE™ 60% 40% 56% 45% 39% 199 HCPs administered > 5 patients 20% 0% 2nd Injecti
Slide 12: SUBOXONE Sublingual Film Indication and Highlighted Safety Information
SUBOXONE (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBOXONE Film is indicated for the treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support
Slide 13: SUBLOCADE Indication and Highlighted Safety Information
SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE) INJECTION FOR SUBCUTANEOUS USE (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-cont